Neural networks and supervised machine learning (ML) techniques can characterise cells studied using single cell RNA-sequencing (scRNA-seq), scientists from Carnegie Mellon University (CMU) have learnt. This could aid others in identifying new cell subtypes and in discerning diseased cells.
A new technology known as “Pattern to Knowledge” (P2K) has been created by researchers at the University of Waterloo to predict the binding of biosequences in only seconds. The new development could radically speed up discovery of new drugs and reduce the need for expensive laboratory tests.
Tumours are helped in their development by mutating the most important cancer-prevention gene, p53, scientists from Melbourne have found. The study, published in Genes and Development, found that mutant p53 prevents the regular p53 protein from activating its natural defences, increasing the risk of the cancer spreading.
Scientists from Cancer Research UK in Cambridge have advanced research into liquid biopsies for brain tumours by detecting tumour DNA in the fluid around the spine and brain.
We spoke to Dr. Carlos Prada, Assistant Professor of Clinical Genetics at Cincinnati Children’s Hospital Medical Center within the University of Cincinnati Department of Pediatrics, and Dr. Emma Clement, Consultant in Clinical Genetics at Great Ormond Street Hospital in the UK, to find out how more about the challenges of implementing NGS globally, and where that implementation has been successful.
Dr. Jonathan Rothberg is a man who needs little introduction, and is now receiving the Association of Molecular Pathology’s (AMP) Award for Excellence in Molecular Diagnostics Services. We spoke to him about his many achievements, his proudest moments, and the future of his fascinating field.
While the Annual Meeting & Expo is the pinnacle of the association’s educational calendar, AMP offers educational initiatives throughout the year in a variety of formats, many of which offer continuing education credit.
The Association for Molecular Pathology (AMP) Annual Meeting & Expo is where the molecular diagnostics community gathers to advance clinical knowledge, discuss new discoveries, share recent successes, and showcase the latest technological advances in molecular medicine.
The Code is an agreement between Government and the insurance industry – with a commitment from insurers to not ask customers about predictive genetic test results when applying for insurance.
Cells settling in an organ other than the correct one during embryogenesis are often the cause of rare ovarian and pancreatic cancers which affect only young women, researchers at the University of Geneva (UNIGE) and the University Hospitals of Geneva (HUG) have found.
Genomics England has chosen Congenica to provide clinical decision support services for the NHS Genomic Medicine Service, which is seeking to make genetic testing routing in healthcare.